NCT03106428View on ClinicalTrials.gov

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

January 3, 2020

Study Completion Date

January 3, 2020

Conditions
Acute Myeloid LeukemiaMultiple MyelomaDiffuse Large B-cell Lymphoma
Interventions
DRUG

MEDI7247

The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV

Trial Locations (14)

10065

Research Site, New York

29650

Research Site, Greer

30322

Research Site, Atlanta

37203

Research Site, Nashville

60611

Research Site, Chicago

63110

Research Site, St Louis

69495

Research Site, Pierre-Bénite

78229

Research Site, San Antonio

80218

Research Site, Denver

90095

Research Site, Los Angeles

94805

Research Site, Villejuif

02114

Research Site, Boston

03080

Research Site, Seoul

06351

Research Site, Seoul

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY